Alpha-methyldopa-chlorpromazine combination in schizophrenic patients

Area of Science:

• Psychiatry
• Clinical Pharmacology

Background:

• Schizophrenia is a complex mental disorder requiring effective treatment.
• Chlorpromazine and alpha-methyldopa are established therapeutic agents.

Purpose of the Study:

• To evaluate the efficacy of different doses of chlorpromazine and alpha-methyldopa in treating schizophrenia.
• To determine the optimal combination dosage for therapeutic benefit.

Main Methods:

• A double-blind, controlled clinical study.
• 55 hospitalized schizophrenic patients received one of five treatment regimens for 8 weeks.
• Treatments included varying doses of chlorpromazine and alpha-methyldopa.

Main Results:

• All five treatment regimens demonstrated significant effectiveness in managing schizophrenic behavior.
• A dose-response relationship was observed for alpha-methyldopa in combination with chlorpromazine.
• The combination of 300 mg chlorpromazine and 500 mg alpha-methyldopa indicated an optimal therapeutic response.

Conclusions:

• Chlorpromazine and alpha-methyldopa combinations are effective treatments for schizophrenia.
• The 300 mg chlorpromazine--500 mg alpha-methyldopa regimen represents a potentially optimal therapeutic strategy.